EUVIMEDEUVIMED entdecken
Crossref

Relapse rates and associated risk factors following omalizumab treatment in adolescents with chronic spontaneous urticaria

Canan Caka iD, Melike Ocak iD, Bahri Can Duran iD, Özge Soyer iD, Bülent Enis Sekerel iD, Ümit Murat Şahiner iD

Pediatric Allergy and Immunology · 2025

DOI: 10.1111/pai.70216 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pediatric Allergy and Immunology, 2025. Verfasst von Canan Caka und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pediatric Allergy, Hacettepe University School of Medicine, Ankara, Turkey. Hauptthemen laut MEDLINE: Omalizumab, Chronic Urticaria, Anti-Allergic Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 39 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Omalizumab is an effective treatment option for antihistamine‐resistant chronic spontaneous urticaria (CSU) patients. This study aimed to evaluate relapse in patients after completing omalizumab treatment and identify associated risk factors.

Methods

Patients aged 12–18 years diagnosed with CSU who received omalizumab therapy between 2015 and 2023, whose treatment ceased with complete remission by December 2024.

Results

This study consisted of 59 patients with a median (interquartile) age of 14.0 (12.0–16.0) years, of whom 49.2% were female. Post‐treatment relapse was observed in 47.4% ( n = 28) of the patients, with a median time to relapse of 6.0 (4.0–7.5) months. Relapsed patients had an earlier onset of CSU than non‐relapsed [11.9 (8.0–13.9) and 14.1 (11.5–15.9) years, p = .028]. The pre‐treatment symptom duration was significantly longer in relapsed patients than in non‐relapsed patients [21.0 (8.0–36.0) and 8.0 (6.0–21.0) months, p = .010]. Patients with symptoms longer than 7.5 months prior to starting omalizumab had a higher risk of relapse (AUC: 0.695, 95% CI: 0.561–0.830; p = .010; sensitivity: 82.1%, specificity: 45.2%). Pretreatment symptom duration was identified as a significant risk factor, increasing the likelihood of relapse (OR: 1.134, 95% CI: 1.011–1.272, p = .032). No significant differences were found between relapsed and non‐relapsed patients in terms of other clinical and laboratory factors. Late relapse was more common in ANA‐positive patients than early relapse [14 (87.5%) vs. 2 (12.5%), p = .021].

Conclusion

Delayed initiation of omalizumab treatment following the onset of urticaria symptoms is associated with an increased risk of relapse. Therefore, omalizumab treatment should be initiated promptly in eligible patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

OmalizumabChronic UrticariaAnti-Allergic AgentsHumansFemaleMaleAdolescentRecurrenceChildRisk FactorsRetrospective StudiesTreatment Outcome

Stichwörter der Autor:innen

chronic spontaneous urticariaomalizumabpediatricrelapserisk factors

Substanzen

OmalizumabAnti-Allergic Agents

Autor:innen und Institutionen

  • Division of Pediatric Allergy, Hacettepe University School of Medicine, Ankara, Turkey.

ORCID-Profile: Canan Caka, Melike Ocak, Bahri Can Duran, Özge Soyer, Bülent Enis Sekerel, Ümit Murat Şahiner

Zitieren

APA

Caka, C., Ocak, M., Duran, B. C., Soyer, Ö., Sekerel, B. E., & Şahiner, Ü. M. (2025). Relapse rates and associated risk factors following omalizumab treatment in adolescents with chronic spontaneous urticaria. Pediatric Allergy and Immunology. https://doi.org/10.1111/pai.70216

Vancouver

Caka C, Ocak M, Duran BC, Soyer Ö, Sekerel BE, Şahiner ÜM. Relapse rates and associated risk factors following omalizumab treatment in adolescents with chronic spontaneous urticaria. Pediatric Allergy and Immunology. 2025. doi:10.1111/pai.70216

BibTeX
@article{Caka2025,
  author = {Caka, Canan and Ocak, Melike and Duran, Bahri Can and Soyer, Özge and Sekerel, Bülent Enis and Şahiner, Ümit Murat},
  title = {Relapse rates and associated risk factors following omalizumab treatment in adolescents with chronic spontaneous urticaria},
  journal = {Pediatric Allergy and Immunology},
  year = {2025},
  doi = {10.1111/pai.70216}
}
Kostenlos starten →